Jounce Therapeutics, Inc. is a clinical stage immunotherapy company, which treat cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients. The company is headquartered in Cambridge, Massachusetts and currently employs 128 full-time employees. The firm is engaged in transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right therapy to the right patient. The Company’s lead product candidate, JTX-2011, is a monoclonal antibody that binds to and activates Inducible T cell CO-Stimulator (ICOS) and is in a Phase II trial.